Macrogenics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 339

Market Cap: $215.1M

Website

Introduction: MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E...

Clinical Trials

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Phase 2

Not yet recruiting

Conditions: Platinum-resistant Ovarian Cancer
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Clear Cell Adenocarcinoma of Ovary
Clear Cell Adenocarcinoma of Vulva
Clear Cell Adenocarcinoma of Vagina
Clear Cell Adenocarcinoma of Cervix
Clear Cell Adenocarcinoma of Uterus
Clear Cell Adenocarcinoma of Fallopian Tube
Clear Cell Adenocarcinoma of Peritoneum

Interventions: Biological: Lorigerlimab

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: MacroGenics

Target Recruit Count: 60

Registration Number: NCT06730347

A Study of MGC028 in Participants With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors
NSCLC Adenocarcinoma
Cholangiocarcinoma
Pancreatic Carcinoma

Interventions: Biological: MGC028

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-09

Lead Sponsor: MacroGenics

Target Recruit Count: 124

Registration Number: NCT06723236

A Study of MGC026 in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Cancer
Bladder Cancer
Castration Resistant Prostatic Cancer
Cervical Cancer
Metastatic Cancer
Endometrial Cancer
Melanoma
Gastro-esophageal Cancer
Clear Cell Renal Cell Carcinoma
Hepatocellular Carcinoma

Interventions: Biological: MGC026 Dose Escalation
Biological: MGC026 Dose for Expansion

First Posted Date: 2024-02-05

Last Posted Date: 2024-12-20

Lead Sponsor: MacroGenics

Target Recruit Count: 230

Registration Number: NCT06242470

Locations: 🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
START Midwest, Grand Rapids, Michigan, United States

and more 7 locations

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Recruiting

Conditions: Androgen-Independent Prostatic Cancer
Androgen-Independent Prostatic Neoplasms
Prostate Cancer Recurrent
Androgen-Insensitive Prostatic Cance
Androgen-Resistant Prostatic Cancer
Hormone Refractory Prostatic Cancer
Immunotherapy
Immune Checkpoint Inhibitor
Inhibitory Checkpoint Molecule

Interventions: Biological: lorigerlimab
Drug: docetaxel
Drug: Prednisone

First Posted Date: 2023-05-08

Last Posted Date: 2024-10-17

Lead Sponsor: MacroGenics

Target Recruit Count: 150

Registration Number: NCT05848011

Locations: 🇺🇸
United Medical Group, Miami, Florida, United States
🇺🇸
Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 58 locations

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer
Androgen-Independent Prostatic Cancer
Laryngeal Squamous Cell Carcinoma
Melanoma
Castration-Resistant Prostatic Cancer
Androgen-Insensitive Prostatic Cancer
Hormone Refractory Prostatic Cancer
Anal Cancer
Anal Neoplasm
Head and Neck Squamous Cell Carcinoma

Interventions: Biological: vobramitamab duocarmazine 2.0 mg (Arm A)
Biological: vobramitamab duocarmazine 2.7 mg (Arm B)
Biological: vobramitamab duocarmazine
Drug: Abiraterone
Drug: Enzalutamide

First Posted Date: 2022-09-22

Last Posted Date: 2024-10-16

Lead Sponsor: MacroGenics

Target Recruit Count: 382

Registration Number: NCT05551117

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇧🇪
Centre Hospitalier Universitaire (CHU) - Universite Catholique de Louvain (UCL) - Namur - Site Godinne (Cliniques Universitaires UCL de Mont-Godinne), Godinne, Namur, Belgium
🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States

and more 59 locations

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 1

Recruiting

Conditions: Leukemia, Acute Myeloid
Myelodysplastic Syndromes
Classical Hodgkin Lymphoma
Leukemia, B-cell
Leukemia, Hairy Cell
Mastocytosis, Aggressive Systemic
Blastic Plasmacytoid Dendritic Cell Neoplasm
Chronic Myeloid Leukemia

Interventions: Drug: MGD024

First Posted Date: 2022-05-05

Last Posted Date: 2024-01-17

Lead Sponsor: MacroGenics

Target Recruit Count: 90

Registration Number: NCT05362773

Locations: 🇺🇸
Colorado Blood Cancer Network, Denver, Colorado, United States
🇺🇸
University of Maryland, Greenbaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Malignant Melanoma
Pancreatic Ductal Carcinoma
Renal Cell Carcinoma
Advanced Solid Tumor
Epithelial Ovarian Cancer
Castration-Resistant Prostatic Cancer
Hepatocellular Cancer

Interventions: Biological: vobramitamab duocarmazine
Biological: lorigerlimab

First Posted Date: 2022-03-24

Last Posted Date: 2024-11-20

Lead Sponsor: MacroGenics

Target Recruit Count: 278

Registration Number: NCT05293496

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States

and more 7 locations

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Phase 1

Completed

Conditions: Human Immunodeficiency Virus Type 1
Immunodeficiency Virus Type 1, Human
Human Immunodeficiency Virus I Infection

Interventions: Biological: MGD020
Biological: MGD014

First Posted Date: 2022-03-02

Last Posted Date: 2024-06-26

Lead Sponsor: MacroGenics

Target Recruit Count: 24

Registration Number: NCT05261191

Locations: 🇺🇸
Icahn School of Medicine at Mt. Sinai, New York, New York, United States
🇺🇸
Case Western Reserve University Hospital, Cleveland, Ohio, United States
🇺🇸
UNC Hospital - Chapel Hill, Chapel Hill, North Carolina, United States

Flotetuzumab Expanded Access Program

Conditions: Acute Myeloid Leukemia
AML
AML, Adult Recurrent

First Posted Date: 2020-12-22

Last Posted Date: 2022-05-31

Lead Sponsor: MacroGenics

Registration Number: NCT04678466

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Phase 2

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma
Head and Neck Neoplasms
Head and Neck Cancer

Interventions: Biological: Enoblituzumab
Biological: Retifanlimab
Biological: Tebotelimab

First Posted Date: 2020-11-18

Last Posted Date: 2023-12-20

Lead Sponsor: MacroGenics

Target Recruit Count: 62

Registration Number: NCT04634825

Locations: 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸
University of Pennsylvania - Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇧🇬
UMHAT Tsarisa Yoanna - ISUL, Sofia, Bulgaria

and more 39 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy